Getting up to speed on research regarding Neuren this morning, I watched the MST Access interview with Jon Pilcher. He clearly emphasised the importance of US rights to NNZ-2591 being the crown jewel of the company should everything go well. In fact, I got the impression he was willing to go it alone as he specifically mentioned US rights twice. Am I close to the mark in assuming that should Neuren be successful with the four diseases that the next logical step would be a broad indication for autism? IF this is the next step I can see why he would want to hang on to the US rights, they are worth several billion independent of autism.
Very interested to see what happens to Neuren if Phase 3 trials are announced for the four diseases. One thing is for sure: its going to cost a hell of a lot of money.
Lets talk ROW, page-23
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.17 |
Change
0.070(0.35%) |
Mkt cap ! $2.578B | |||
| Open | High | Low | Value | Volume |
| $20.39 | $20.53 | $20.14 | $4.102M | 202.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 249 | $20.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.31 | 790 | 1 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |